Convalescent Plasma in Hospitalized COVID-19 Patients

NCT05157165 | Unknown

• 1 other identifier: 00001
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.

Conditions

COVID-19

Interventions

Convalescent plasma BIOLOGICAL

Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patients admitted for severe COVID-19

You may not qualify if:

• \< 18 years
• participation in any other clinical trial of an experimental treatment for COVID-19

Sponsors & Collaborators

• Azienda Socio Sanitaria Territoriale di Mantova: lead

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: expanded access
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director Immunohematology and Transfusion Center

Study Record Dates

• First Submitted: December 10, 2021
• First Posted: December 14, 2021
• Last Updated: July 21, 2023

Record last verified: 2023-07